Biopharma | December 04, 2025
Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
The study, titled “A Large-Scale Efficacy Trial of a Resilience Training Program for First Responders,” will enroll 800 first responders in New York and Texas
This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide
CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating
Subscribe To Our Newsletter & Stay Updated
